Potentially remediable features of the medication-use environment in the United States

American Journal of Health-System Pharmacy

Volumn 57, Issue 6, 2000, Pages 543-548

  Hennessy, Sean ^a,b,c  

^a Ctr Clin Epidemiol Biostatist   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOSPITAL CARE; MEDICAL EDUCATION; MEDICARE; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PUBLIC HEALTH; REIMBURSEMENT; UNITED STATES;

EID: 0034654208     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.6.543     Document Type: Conference Paper

References (35)

1. Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am J Health-Syst Pharm. 1998; 55:165-6.
2. Bates DW. Medication errors. How common are they and what can be done to prevent them? Drug Saf. 1996; 15:303-10.
3. Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm. 1989; 46:929-44.
4. Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 2. Am J Hosp Pharm. 1989; 46:1141-52.
5. Escovitz A, Pathak DS, Schneider PJ, eds. Improving the quality of the medication use process: error prevention and reducing adverse drug events. New York: Pharmaceutical Products; 1998.
6. Approaches to drug insurance design: background papers by the Task Force on Prescription Drugs. Washington, DC: U.S. Government Printing Office; 1969.
7. Final report of the Task Force on Prescription Drugs. Washington, DC: U.S. Government Printing Office; 1969.
8. FASTATS A to Z. http://www.cdc.gov/ nchswww/fastats/hospital.htm. (accessed 1999 Aug 10).
9. Pew Charitable Trusts Publications. http:// www.pewtrusts.com/Frame.cfm? Frame source=Pubs/publications.cfm. (accessed 1999 Aug 10).
10. National Community Pharmacists Association announcements. http://www.ncpanet. org/announce.html. (accessed 1999 Aug 10).
11. Ukens C. Chain drugstores seek regulatory relief from pharmacy boards. Drug Top. 1999; 143(1):22.
12. Dennehy CE, Kishi DT, Louie C. Drug-related illness in emergency department patients. Am J Health-Syst Pharm. 1996; 53:1422-6.
13. Brennan TA, Leape LL, Laird NM et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991; 324:370-6.
14. Leape LL, Brennan TA, Laird N et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
15. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA. 1995; 274:29-34.
16. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200-5.
17. Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA. 1998; 279:1216-7. Editorial.
18. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res. 1999; 35 (suppl): S87-92.
19. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999; 35(suppl):S61-6.
20. Dally A. Thalidomide: was the tragedy preventable? Lancet. 1998; 351:1197-9.
21. Hurwitz ES. Reye's syndrome. Epidemiol Rev. 1989; 11:249-53.
22. Jacobson JM, Spritzler J, Fox L et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis. 1999; 180:61-7.
23. Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am Heart J. 1999; 137:S9-13.
24. Havlir DV, Lange JM. New antiretrovirals and new combinations. AIDS. 1998; 12 (suppl A):S165-74.
25. Soumerai SB, Lipton HL. Evaluating and improving physician prescribing. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. Sussex, England: John Wiley; 1994.
26. Schwartz B, Mainous AG, Marcy SM. Why do physicians prescribe antibiotics for children with upper respiratory tract infections? JAMA. 1998; 279:881-2.
27. Peterson GM, Wu MS, Bergin JK. Pharmacist's attitudes towards dispensing errors: their causes and prevention. J Clin Pharm Ther. 1999; 24:57-71.
28. Lin AC, Jang R, Sedani D et al. Re-engineering a pharmacy work system and layout to facilitate patient counseling. Am J Health-Syst Pharm. 1996; 53:1558-64.
29. Curley C, McEachern JE, Speroff T. A firm trial of interdisciplinary rounds on the inpatient medical wards: an intervention designed using continuous quality improvement. Med Care. 1998; 36:AS4-12.
30. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
31. Schifif GD, Rucker TD. Computerized prescribing: building the electronic infrastructure for better medication usage. JAMA. 1998; 279:1024-9.
32. Bates DW, Leape LL, Cullen DJ et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998; 280:1311-6.
33. Soumerai SB, Ross-Degnan D, Avorn J et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991; 325:1072-7.
34. Soumerai SB, McLaughlin TJ, Ross-Degnan D et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994; 331:650-5.
35. Haynes RB, Montague P, Oliver T et al. Interventions for helping patients follow prescriptions for medications. Cochrane Database Syst Rev[serial online]. 1999; issue 4.